According to a retrospective study of patients with advanced iCCA who underwent chemotherapy, IDH1 mutations were observed in 14.5% of iCCA patients, and iCCA patients with IDH1 mutations appeared to have better tumor biological characteristics, including longer PFS, than those with IDH1 wild-type [115]. Here, IDH1 is linked to neoplasm.